Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma

Volume: 67, Issue: 1
Published: Mar 1, 2021
Abstract
Hepatocellular carcinoma (HCC) represents the sixth most commonly diagnosed cancer and the fourth leading cause of cancer-related death worldwide. HCC occurs predominantly in patients with underlying chronic liver disease and cirrhosis, and it presents a poor prognosis in advanced stage. Since its approval, for the following 10 years, sorafenib remained the only systemic agent with proven clinical efficacy for patients with advanced HCC....
Paper Details
Title
Current and future perspective on targeted agents and immunotherapies in hepatocellular carcinoma
Published Date
Mar 1, 2021
Volume
67
Issue
1
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.